Spero Therapeutics (NASDAQ:SPRO) Stock Gets Downgrade from Wall Street Zen

Key Points

• Wall Street Zen downgraded Spero Therapeutics from “hold” to “sell,” while analyst sentiment remains mixed. The stock has a consensus “hold” rating and an average price target of $6.00.
• Spero shares opened at $1.06, near their 52-week low of $1.04, with the stock down 4.5%; its market capitalization is approximately $61.7 million.
• Institutional investors expanded their positions, with hedge funds and other institutions now owning 25.6% of the company. Spero develops treatments for multidrug-resistant bacterial infections and rare diseases.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Saturday, Wall Street Zen reports.

A number of other equities research analysts also recently weighed in on SPRO. Cantor Fitzgerald started coverage on Spero Therapeutics in a research report on Wednesday. They set an "overweight" rating and a $6.00 price objective on the stock. Zacks Research upgraded shares of Spero Therapeutics to a "hold" rating in a report on Monday, September 14th. Weiss Ratings downgraded shares of Spero Therapeutics from a "hold (c-)" rating to a "sell (d+)" rating in a report on Monday. Compass Point raised shares of Spero Therapeutics to a "neutral" rating in a research report on Monday, September 14th. Finally, HC Wainwright raised their price target on shares of Spero Therapeutics from $5.00 to $6.00 and gave the company a "buy" rating in a report on Monday, September 14th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $6.00.

Spero Therapeutics Stock Down 4.5%

Shares of NASDAQ:SPRO opened at $1.06 on Friday. The firm has a 50 day moving average of $1.17 and a 200 day moving average of $1.98. The company has a market capitalization of $61.73 million, a price-to-earnings ratio of 10.09 and a beta of 1.50. Spero Therapeutics has a 52 week low of $1.04 and a 52 week high of $3.08.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.01. Spero Therapeutics had a return on equity of 16.17% and a net margin of 24.90%. On average, sell-side analysts expect that Spero Therapeutics will post -0.97 EPS for the current year.

Institutional Trading of Spero Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in SPRO. Alphabet Inc. acquired a new stake in shares of Spero Therapeutics in the 2nd quarter worth $1,967,000. BlackRock Inc. acquired a new position in Spero Therapeutics during the 2nd quarter valued at about $1,314,000. GSA Capital Partners LLP acquired a new position in Spero Therapeutics during the 2nd quarter valued at about $632,000. Global Retirement Partners LLC acquired a new position in Spero Therapeutics during the 2nd quarter valued at about $55,000. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in Spero Therapeutics in the second quarter valued at about $36,000. Hedge funds and other institutional investors own 25.60% of the company's stock.

About Spero Therapeutics

Spero Therapeutics, Inc NASDAQ: SPRO is a biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections and certain rare diseases. The company's research programs are designed to address infections for which existing antibiotics may be inadequate, including complicated urinary tract infections and infections caused by difficult-to-treat pathogens.

Spero's lead product candidate has been tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic developed for the treatment of complicated urinary tract infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.